Oncocyte Reports Preliminary Fourth Quarter and Full Year 2022 Financial Results and Plans to File Form 12b-25 to Extend Filing Date of Its Form 10-KGlobeNewsWire • 03/31/23
Oncocyte Announces Date Change for Fourth Quarter and Full Year 2022 Earnings CallGlobeNewsWire • 03/29/23
Oncocyte Announces the Appointment of Louis E. Silverman as a Member of Its Board of DirectorsGlobeNewsWire • 11/30/22
OncoCyte (OCX) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?Zacks Investment Research • 09/26/22
Oncocyte to Participate at the Lake Street 6th Annual Best Ideas Growth ConferenceGlobeNewsWire • 08/31/22
Oncocyte Announces Publication of the Validation of DetermaIO in Predicting Immune Therapy Response in Metastatic Bladder CancerGlobeNewsWire • 08/24/22
OncoCyte Corporation (OCX) CEO Ronnie Andrews on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/11/22
Oncocyte Announces the Appointment of John Peter Gutfreund as Independent Member of Its Board of Directors Effective July 28, 2022GlobeNewsWire • 08/01/22